Gp130 Promotes Inflammation via the STAT3/JAK2 Pathway in Allergic Conjunctivitis

Quick Facts

  • Publication title: Gp130 Promotes Inflammation via the STAT3/JAK2 Pathway in Allergic Conjunctivitis
  • Journal: INVEST OPHTH VIS SCI
  • Year: 2023
  • DOI: 10.1167/iovs.64.4.5
  • PMID/PMCID: 37022703; PMC10082384

Research overview

We found that gp130 is essential for AC, as gp130 levels are elevated in AC. Inhibiting gp130 phosphorylation alleviates ocular surface inflammation in mice, presenting a potential treatment approach for AC.

Key findings

Gp130 is upregulated in the conjunctival tissues of OVA-induced mice, the serum and tears of patients, and the histamine-stimulated HConEpiCs.

Signal transducer and activator of transcription 3 (STAT3) and Janus kinase 2 (JAK2) were upregulated in the conjunctival tissues of mice with OVA-induced AC and in HConEpiCs.

Ocular surface inflammation was significantly relieved in LMT-28-treated mice.

The expression of IgE, IL-4, IL-5, and IL-13 in serum of LMT-28-treated mice decreased.

Study design

To compare mRNA expression profiles, the conjunctival tissues of BALB/c mice with ovalbumin (OVA)-induced AC were subjected to RNA-sequencing (RNA-seq) analysis followed by bioinformatic analysis.

A nonrandomized study involving 57 patients with AC and 24 sex- and age-matched healthy individuals was conducted.

A protein chip was used to detect cytokine levels in patient tears.

Echo Biotech Role

Echo Biotech contributed whole-transcriptome sequencing.

Related platforms: Exoomics®

Related services and capabilities: EV Whole-Transcriptome Sequencing

References

Original publication: Gp130 Promotes Inflammation via the STAT3/JAK2 Pathway in Allergic Conjunctivitis Investigative ophthalmology & visual science. 2023. DOI: 10.1167/iovs.64.4.5. PMID/PMCID: 37022703; PMC10082384.